info@affiniatx.com
43 Foundry Ave, Suite 120 Waltham, MA 02453
Our Company
Our Story
Our Team
Our Science
Our Platform
Our Pipeline
Our DNA
Our News
Contact Us
Our Company
Our Story
Our Team
Our Science
Our Platform
Our Pipeline
Our DNA
Our News
Contact Us
Our Company
Our Story
Our Team
Our Science
Our Platform
Our Pipeline
Our DNA
Our News
Contact Us
Our News
Newsroom
Posters
Presentations
Press Releases
May 19, 2025
Presentations
ASGCT 2025: Development of a Flexible High Yielding, High Performing Process for Manufacturing of AFTX-201, a Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy
Read More
May 19, 2025
Posters
ASGCT 2025: A Novel Investigational AAV Gene Therapy for Treatment of BAG3 Dilated Cardiomyopathy
Read More
May 19, 2025
Posters
ASGCT 2025: High-Yield, Pan-Serotype Plasmid System for Manufacturing Adeno-Associated Virus Gene Therapies: Cost and Efficiency Benefits for R&D and Commercial Processes
Read More
May 19, 2025
Posters
ASGCT 2025: Engineered AAV Capsids That Target a Novel Human Brain Endothelial Receptor Achieve Robust Transduction in Non-human Primate Central Nervous System After Intravenous Dosing
Read More
May 19, 2025
Posters
ASGCT 2025: Novel AAV Capsids That Bind Human Transferrin Receptor (TFRC) Demonstrate Widespread and Preferential CNS Tropism in TFRC-KI Mice After Low-dose Systemic Dosing
Read More
May 13, 2025
Press Releases
Affinia Therapeutics Presents New Data on its Lead AFTX-201 Program in BAG3 Dilated Cardiomyopathy, BBB-Penetrant AAV Capsids, and Proprietary Manufacturing Technology at the 28th American Society of Gene & Cell Therapy 2025 Annual Meeting
Read More
Load More
Discover what it’s like to be an Affinian
Changing the world for patients – powered by science
Our DNA
Contact Info
info@affiniatx.com
Office Address
Affinia Therapeutic
43 Foundry Ave, Suite 120 Waltham, MA 02453
Linkedin-in